Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06599775
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-26
Brief Title:
Study of Adebrelimab With Chemotherapy Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prospective Single-arm Multicenter Exploratory Study of Adebrelimab Combined With Chemotherapy Endoscopic Resection and Sequential Chemoradiotherapy In the Treatment of Inoperable Clinical Staging T1b-2 Esophageal Squamous Cell Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluating the efficacy and safety of PD-L1 Programmed Death-L1antibody combined with endoscopy and radiotherapy for inoperable cT1b-2 clinical stage tumor 1b-2 esophageal squamous cell carcinoma
Detailed Description:
Previous studies have already confirm immunotherapy combine with chemotherapy can improve pathological complete response rates Therefore it is proposed to carry out a study of immuno-combination chemotherapy combined with endoscopic resection and synchronous radiotherapy and chemotherapy in patients with clinical stage cT1-2N0M0 clinical stage tumor 1b-2 clinical stage nodes 0 stage metastasis 0 to evaluate the efficacy and safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None